FAST NEWS: Ascletis Pharma’s Monkeypox Drug Gets IND Approval
The latest: Ascletis Pharma Inc. (1672.HK) announced on Thursday that the China National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) application for its oral viral polymerase…
Recent Articles
RELATED ARTICLES
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Ascentage Pharma soars on deal with cancer drug competitor
6855.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
Discover hidden China stock gems in our weekly newsletter